Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

TG4010, a Modified Vaccinia virus Ankara (MVA) expressing human mucin1 (MUC1) has demonstrated clinical benefit for patients suffering from advanced non-small cell lung cancer (NSCLC) in combination with chemotherapy. To support its development, preclinical experiments were performed with either TG4...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hum Vaccin Immunother
Autors principals: Remy-Ziller, Christelle, Thioudellet, Christine, Hortelano, Julie, Gantzer, Murielle, Nourtier, Virginie, Claudepierre, Marie-Christine, Sansas, Benoit, Préville, Xavier, Bendjama, Kaïdre, Quemeneur, Eric, Rittner, Karola
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791558/
https://ncbi.nlm.nih.gov/pubmed/28925793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2017.1373921
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars